EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities

Chunyan Liu iD, Qinan Yin iD, Zhaoying Wu, Wenhui Li, Jun Huang, Bo Chen, Yanjun Yang, Xuewei Zheng, Li Zeng, Jingjing Wang

Journal of Inflammation Research · 2025-01 · Volume 18 · 895-909

DOI: 10.2147/jir.s503479 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Inflammation Research, 2025-01. Verfasst von Chunyan Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, People's Republic of China. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer (OC) remains one of the most lethal gynecological malignancies, largely due to its late-stage diagnosis and high recurrence rates. Chronic inflammation is a critical driver of OC progression, contributing to immune evasion, tumor growth, and metastasis. Inflammatory cytokines, including IL-6, TNF-α, and IL-8, as well as key signaling pathways such as nuclear factor kappa B (NF-kB) and signal transducer and activator of transcription 3 (STAT3), are upregulated in OC, promoting a tumor-promoting environment. The tumor microenvironment (TME) is characterized by immune cells like tumor-associated macrophages (TAMs) and regulatory T cells (Tregs), which suppress anti-tumor immune responses, facilitating immune evasion. Furthermore, OC cells utilize immune checkpoint pathways, including PD-1/PD-L1, to inhibit cytotoxic T cell activity. Targeting these inflammatory and immune evasion mechanisms offers promising therapeutic strategies. COX-2 inhibitors, Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway blockers, and NF-kB inhibitors have shown potential in preclinical studies, while immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 have been explored with mixed results in OC. Additionally, emerging research on the microbiome and inflammation-related biomarkers, such as microRNAs (miRNAs) and exosomes, points to new opportunities for early detection and precision medicine. Future approaches to OC treatment must focus on personalized strategies that target the inflammatory TME, integrating anti-inflammatory therapies with immunotherapy to enhance patient outcomes. Continued research into the interplay between inflammation and immune evasion in OC is essential for developing effective, long-lasting treatments.

Schlagwörter

Stichwörter der Autor:innen

evasion of immune responseinflammation-driven mechanismsovarian cancertherapeutic strategies

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, China-Japan Friendship Hospital, Beijing, People's Republic of China.
  • Department of Radiation Oncology, First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, People's Republic of China.
  • Precision Medicine Laboratory, School of Medical Technology and Engineering, Henan University of Science and Technology, Luoyang, People's Republic of China.

ORCID-Profile: Chunyan Liu, Qinan Yin

Zitieren

APA

Liu, C., Yin, Q., Wu, Z., Li, W., Huang, J., Chen, B., Yang, Y., Zheng, X., Zeng, L., & Wang, J. (2025). Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities. Journal of Inflammation Research, Volume 18, 895-909. https://doi.org/10.2147/jir.s503479

Vancouver

Liu C, Yin Q, Wu Z, Li W, Huang J, Chen B, et al. Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities. Journal of Inflammation Research. 2025;Volume 18:895-909. doi:10.2147/jir.s503479

BibTeX
@article{Liu2025,
  author = {Liu, Chunyan and Yin, Qinan and Wu, Zhaoying and Li, Wenhui and Huang, Jun and Chen, Bo and Yang, Yanjun and Zheng, Xuewei and Zeng, Li and Wang, Jingjing},
  title = {Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities},
  journal = {Journal of Inflammation Research},
  year = {2025},
  volume = {Volume 18},
  pages = {895--909},
  doi = {10.2147/jir.s503479}
}
Kostenlos starten →